Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sexuality 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Prostatic Neoplasms 1Erectile Dysfunction 1

Interventions

Sildenafil Citrate 9Tadalafil 4Surveys and Questionnaires 2Pentoxifylline 2Alprostadil 2udenafil 1trametinib 1sotorasib 1selpercatinib 1pembrolizumab 1osimertinib 1mirabegron 1methyl 3-mercaptopropionimidate 1lorlatinib 1dabrafenib 1cemiplimab 1brigatinib 1bicalutamide 1alpha-Tocopherol 1alectinib 1Yoga 1Vitamin E 1Tamoxifen 1Tacrolimus 1Tablets 1Surgical Instruments 1Saline Solution 1Restraint, Physical 1Psychiatric Rehabilitation 1Preservation, Biological 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Erectile Dysfunction × ArginMax × Clear all
NCT01105130 2021-09-28

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

Phase 2 Completed
140 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡